Nanology Labs is an early-stage pharmaceutical company developing theranostic agents (MRI contrast agent/Radio-sensitizer) for cancer detection and therapy. Nanology Labs has designed and is developing Manganescan® that allows detection of tumors at early stages using MRI. Simultaneously, it sensitizes cancer cells which improves radiation therapy outcomes. The agent is 3x more sensitive than current Gadolinium contrast agents (GBCAs), and can cross the blood-brain barrier; this enables early and precise detection and targeting of brain cancer. Manganescan produces oxygen molecules when localized in the tumor, by which enhances radiation therapy efficacy and improves the patients' life expectancy by more than 5-fold.
Direct poster presentation link is here https://www.synapselifescience.com/competition?wix-vod-video-id=2e6d3b44f7d446d9a74722984fd12f49&wix-vod-comp-id=comp-k7xqqo031
Thanks, Richard, for the question. Yes, We have three IP covering the technology. One is issued and two are in international phase.
Manganscan sounds like a great solution. I see you have a registered trademark® Do you also have IP protection on your formula?
Congratulations Nanology Labs on making it through the Synapse Competition! We're all impressed by the commitment and effort that you've put in over the last few months to get to this stage. We hope that participating in the Competition was a valuable experience for you - and remember, there are still lots of ways that Innovation Factory, the Synapse Consortium and the rest of the Hamilton ecosystem can provide support!
Ask the team from Nanology Labs a question, or make a connection by posting a comment!
Watch Nanology Labs' elevator pitch and poster over at www.synapselifescience.com/competition
Click on the Nanology Labs Poster to see a larger view!